ReviewTherapeutic advances in hematology2021
Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review.
Review in Therapeutic advances in hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.Annals of hematology · 2023Pooled it
- Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial.Annals of medicine · 2023Trial
- Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives.Current opinion in hematology · 2026Review
- Romiplostim during pregnancy in refractory primary immune thrombocytopenia: Literature review and case series.Therapeutic advances in hematology · 2026Article
- A practical approach to immune thrombocytopenia in pregnancy.Hematology. American Society of Hematology. Education Program · 2025Review
- Management of Immune Thrombocytopenia via Splenectomy in a Full-Term Pregnant Woman: A Case Report.International medical case reports journal · 2025Article
- ITP in pregnancy: diagnostics and therapeutics in 2024.Hematology. American Society of Hematology. Education Program · 2024Review
- Isolated thrombocytopenia in pregnancy: A monocentric retrospective study of 63 pregnancies in 59 women.EJHaem · 2024Article
- Review
- An Innovative Inducer of Platelet Production, Isochlorogenic Acid A, Is Uncovered through the Application of Deep Neural Networks.Biomolecules · 2024Article
- Article
- Primary Immune Thrombocytopenia in Pregnancy: Pathology, Diagnosis, and Management.Global medical genetics · 2023Article
- Article
- Application of recombinant human thrombopoietin in pregnant women with immune thrombocytopenia: a single-center experience of four patients and literature review.The Journal of international medical research · 2023Review
- Trends in outcomes and racial disparities in adult hospitalizations for immune thrombocytopenia over a decade.Annals of hematology · 2023Article
- A successful management of refractory immune thrombocytopenic purpura with Eltrombopag during pregnancy complicated with superimposed preeclampsia.Oxford medical case reports · 2023Article
- Thrombocytopenia in pregnancy.Hematology. American Society of Hematology. Education Program · 2022Review
- Bleeding Complications Associated with Pregnancy with Primary Immune Thrombocytopenia: A Meta-Analysis.TH open : companion journal to thrombosis and haemostasis · 2022Article
- Effect of Thrombopoietin Receptor Agonist on Pregnant Mice.Pharmaceutics · 2022Article
- Aplastic Anemia Treated with Eltrombopag during Pregnancy.Case reports in obstetrics and gynecology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of immune thrombocytopenia (ITP) in adults has evolved rapidly over the past decade. The second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag are approved for the treatment of chronic ITP in adults. However, their use in pregnancy is labeled as category C by the United States Food and Drug Administration (FDA) due to the lack of clinical data on human subjects. ITP is a common cause of thrombocytopenia in the first and second trimester of pregnancy, which not only affects the mother but can also lead to thrombocytopenia in the neonatal thrombocytopenia secondary to maternal immune thrombocytopenia (NMITP). Corticosteroids, intravenous immunoglobulins (IVIGs) are commonly used for treating acute ITP in pregnant patients. Drugs such as rituximab, anti-D, and azathioprine that are used to treat ITP in adults, are labeled category C and seldom used in pregnant patients. Cytotoxic chemotherapy (vincristine, cyclophosphamide), danazol, and mycophenolate are contraindicated in pregnant women. In such a scenario, TPO-RAs present an attractive option to treat ITP in pregnant patients. Current evidence on the use of TPO-RAs in pregnant women with ITP is limited. In this narrative review, we will examine the preclinical and the clinical literature regarding the use of TPO-RAs in the management of ITP in pregnancy and their effect on neonates with NMITP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.